Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: Potential implications for the treatment of metabolic syndrome

Massimiliano Caprio, Antonella Antelmi, Gérard Chetrite, Adeline Muscat, Caterina Mammi, Vincenzo Marzolla, Andrea Fabbri, Maria Christina Zennaro, Bruno Fève

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

The mineralocorticoid receptor (MR) mediates aldosterone-and glucocorticoid-induced adipocyte differentiation. Drospirenone (DRSP) is a potent synthetic antimineralocorticoid with progestogenic and antiandrogenic properties, which is widely used for contraception and hormone replacement therapy.Weinvestigated its potential role on adipocyte differentiation. The effects of DRSP were studied in murine preadipocyte cell lines and primary cultures of human preadipocytes. Differentiation markers and mechanisms underlying phenotypic variations in response to DRSP were explored. Early exposure to DRSP during differentiation led to a marked dose-dependent inhibition of adipose differentiation and triglyceride accumulation in 3T3-L1 and 3T3-F442A cells. DRSP also markedly inhibited adipose conversion of human primary preadipocytes derived from visceral (mesenteric and epicardial) and subcutaneous fat. This effect was MR-dependent and did not involve the glucocorticoid, androgen, or progesterone receptors. DRSP inhibited clonal expansion of preadipocytes and decreased expression of PPAR, a key transcriptional mediator of adipogenesis, but had no effect on lipolysis, glucose uptake, and PPARγ binding to its ligands. DRSP exerts a potent antiadipogenic effect that is related to an alteration of the transcriptional control of adipogenesis via an antagonistic effect on the MR. Selective MR blockade therefore has promise as a novel therapeutic option for the control of excessive adipose tissue deposition and its related metabolic complications.

Original languageEnglish
Pages (from-to)113-125
Number of pages13
JournalEndocrinology
Volume152
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Mineralocorticoid Receptor Antagonists
Mineralocorticoid Receptors
Adipogenesis
Peroxisome Proliferator-Activated Receptors
Adipocytes
Therapeutics
3T3-L1 Cells
Lipolysis
Subcutaneous Fat
Differentiation Antigens
Hormone Replacement Therapy
Glucocorticoid Receptors
Androgen Receptors
Progesterone Receptors
drospirenone
Aldosterone
Contraception
Glucocorticoids
Adipose Tissue
Triglycerides

ASJC Scopus subject areas

  • Endocrinology

Cite this

Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone : Potential implications for the treatment of metabolic syndrome. / Caprio, Massimiliano; Antelmi, Antonella; Chetrite, Gérard; Muscat, Adeline; Mammi, Caterina; Marzolla, Vincenzo; Fabbri, Andrea; Zennaro, Maria Christina; Fève, Bruno.

In: Endocrinology, Vol. 152, No. 1, 01.2011, p. 113-125.

Research output: Contribution to journalArticle

Caprio, Massimiliano ; Antelmi, Antonella ; Chetrite, Gérard ; Muscat, Adeline ; Mammi, Caterina ; Marzolla, Vincenzo ; Fabbri, Andrea ; Zennaro, Maria Christina ; Fève, Bruno. / Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone : Potential implications for the treatment of metabolic syndrome. In: Endocrinology. 2011 ; Vol. 152, No. 1. pp. 113-125.
@article{d277097dfb454f23ba7b2e6f34a101dc,
title = "Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: Potential implications for the treatment of metabolic syndrome",
abstract = "The mineralocorticoid receptor (MR) mediates aldosterone-and glucocorticoid-induced adipocyte differentiation. Drospirenone (DRSP) is a potent synthetic antimineralocorticoid with progestogenic and antiandrogenic properties, which is widely used for contraception and hormone replacement therapy.Weinvestigated its potential role on adipocyte differentiation. The effects of DRSP were studied in murine preadipocyte cell lines and primary cultures of human preadipocytes. Differentiation markers and mechanisms underlying phenotypic variations in response to DRSP were explored. Early exposure to DRSP during differentiation led to a marked dose-dependent inhibition of adipose differentiation and triglyceride accumulation in 3T3-L1 and 3T3-F442A cells. DRSP also markedly inhibited adipose conversion of human primary preadipocytes derived from visceral (mesenteric and epicardial) and subcutaneous fat. This effect was MR-dependent and did not involve the glucocorticoid, androgen, or progesterone receptors. DRSP inhibited clonal expansion of preadipocytes and decreased expression of PPAR, a key transcriptional mediator of adipogenesis, but had no effect on lipolysis, glucose uptake, and PPARγ binding to its ligands. DRSP exerts a potent antiadipogenic effect that is related to an alteration of the transcriptional control of adipogenesis via an antagonistic effect on the MR. Selective MR blockade therefore has promise as a novel therapeutic option for the control of excessive adipose tissue deposition and its related metabolic complications.",
author = "Massimiliano Caprio and Antonella Antelmi and G{\'e}rard Chetrite and Adeline Muscat and Caterina Mammi and Vincenzo Marzolla and Andrea Fabbri and Zennaro, {Maria Christina} and Bruno F{\`e}ve",
year = "2011",
month = "1",
doi = "10.1210/en.2010-0674",
language = "English",
volume = "152",
pages = "113--125",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone

T2 - Potential implications for the treatment of metabolic syndrome

AU - Caprio, Massimiliano

AU - Antelmi, Antonella

AU - Chetrite, Gérard

AU - Muscat, Adeline

AU - Mammi, Caterina

AU - Marzolla, Vincenzo

AU - Fabbri, Andrea

AU - Zennaro, Maria Christina

AU - Fève, Bruno

PY - 2011/1

Y1 - 2011/1

N2 - The mineralocorticoid receptor (MR) mediates aldosterone-and glucocorticoid-induced adipocyte differentiation. Drospirenone (DRSP) is a potent synthetic antimineralocorticoid with progestogenic and antiandrogenic properties, which is widely used for contraception and hormone replacement therapy.Weinvestigated its potential role on adipocyte differentiation. The effects of DRSP were studied in murine preadipocyte cell lines and primary cultures of human preadipocytes. Differentiation markers and mechanisms underlying phenotypic variations in response to DRSP were explored. Early exposure to DRSP during differentiation led to a marked dose-dependent inhibition of adipose differentiation and triglyceride accumulation in 3T3-L1 and 3T3-F442A cells. DRSP also markedly inhibited adipose conversion of human primary preadipocytes derived from visceral (mesenteric and epicardial) and subcutaneous fat. This effect was MR-dependent and did not involve the glucocorticoid, androgen, or progesterone receptors. DRSP inhibited clonal expansion of preadipocytes and decreased expression of PPAR, a key transcriptional mediator of adipogenesis, but had no effect on lipolysis, glucose uptake, and PPARγ binding to its ligands. DRSP exerts a potent antiadipogenic effect that is related to an alteration of the transcriptional control of adipogenesis via an antagonistic effect on the MR. Selective MR blockade therefore has promise as a novel therapeutic option for the control of excessive adipose tissue deposition and its related metabolic complications.

AB - The mineralocorticoid receptor (MR) mediates aldosterone-and glucocorticoid-induced adipocyte differentiation. Drospirenone (DRSP) is a potent synthetic antimineralocorticoid with progestogenic and antiandrogenic properties, which is widely used for contraception and hormone replacement therapy.Weinvestigated its potential role on adipocyte differentiation. The effects of DRSP were studied in murine preadipocyte cell lines and primary cultures of human preadipocytes. Differentiation markers and mechanisms underlying phenotypic variations in response to DRSP were explored. Early exposure to DRSP during differentiation led to a marked dose-dependent inhibition of adipose differentiation and triglyceride accumulation in 3T3-L1 and 3T3-F442A cells. DRSP also markedly inhibited adipose conversion of human primary preadipocytes derived from visceral (mesenteric and epicardial) and subcutaneous fat. This effect was MR-dependent and did not involve the glucocorticoid, androgen, or progesterone receptors. DRSP inhibited clonal expansion of preadipocytes and decreased expression of PPAR, a key transcriptional mediator of adipogenesis, but had no effect on lipolysis, glucose uptake, and PPARγ binding to its ligands. DRSP exerts a potent antiadipogenic effect that is related to an alteration of the transcriptional control of adipogenesis via an antagonistic effect on the MR. Selective MR blockade therefore has promise as a novel therapeutic option for the control of excessive adipose tissue deposition and its related metabolic complications.

UR - http://www.scopus.com/inward/record.url?scp=78650805849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650805849&partnerID=8YFLogxK

U2 - 10.1210/en.2010-0674

DO - 10.1210/en.2010-0674

M3 - Article

C2 - 21084448

AN - SCOPUS:78650805849

VL - 152

SP - 113

EP - 125

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 1

ER -